Spatial and temporal trends in the ecological risk posed by polycyclic aromatic hydrocarbons in Mediterranean Sea sediments using large-scale monitoring data

Abstract Benthic organisms play an important role in aquatic ecosystems and are often used as indicators of toxic environments. In this study, we reconstructed the spatial and temporal trend of risk to benthic communities living in sediments of the Mediterranean Sea posed by the presence of 16 polycyclic aromatic hydrocarbons (PAHs). Moreover, the origins of PAH contamination in the sea were also investigated. The analysis included multiple steps, starting with an in-depth review of available studies (from the early 1980s to 2019) reporting PAH concentrations in sediments of the Mediterranean Sea. Subsequently, the collected data were spatialised and clustered according to the four basins of the Mediterranean as defined by the Mediterranean Strategy on Sustainable Development and the United Nations Environment Programme Mediterranean Action Plan. We employed additive models, a flexible and versatile tool for coping with non-linear trends by means of smooth functions, to estimate temporal trends in PAH concentrations. Finally, the primary origins of contamination and temporal trends in ecological risk were determined using a combination of approaches. The results indicated that PAHs in Mediterranean sediments originate primarily from biomass burning, with a contribution from combustion of coal and liquid fossil fuels, the latter being representative of sites near urban centres or harbours. A significant positive correlation between annual growth rates of PAH concentration in sediment and wildfires was found. The estimated non-linear trends of concentrations and risk showed different temporal patterns across basins. In recent years, especially in the Western Mediterranean, the estimated trends suggest PAH concentrations are posing an increasing risk. These results indicate the need for stronger efforts to achieve the objectives of the Marine Strategy Framework Directive

Behavioural responses of juvenile Daphnia magna to two organophosphorus insecticides

In this study, the behaviour of Daphnia magna was studied under equipotent and sub-lethal concentrations of two pesticides congeners: chlorpyrifos (CPF; 5 ng L-1 to 50 ng L-1) and chlorpyrifos-methyl (CPF-m; 30 ng L-1 to 300 ng L-1) with aims to assess and compare the behavioural swimming responses (BSRs) of the cladocerans elicited by both compounds at different concentrations and exposure times. A video tracking analysis after 24 h and 48 h of exposure allowed us to evaluate different behavioural responses (distance moved, average velocity, active time, and average acceleration). The results indicate that BSRs are sensitive indicators of sub-lethal stress. Highly concentration- and time-response changes for both compounds were observed during the experiments. In particular, in the first 24 h of exposure, both compounds elicited a similar decreasing trend in swimming behaviour, in which CPF induced the highest decline. Further, hypoactivity was associated with the narcotic effects of both compounds. Conversely, after 48 h of exposure, we observed an increasing tendency in the swimming parameters, particularly at the highest tested concentrations. However, the compounds did not exhibit the same trend. Rather, CPF-m induced high variations from the control groups. This reversal trend could be due to the activation of compensatory mechanisms, such as feeding, searching, or avoidance behaviours. These results suggest that BSRs are measurable active responses of organisms, which are controlled by time

Optical signature of erythrocytes by light scattering in microfluidic flows

A camera-based light scattering approach coupled with a viscoelasticity-induced cell migration technique has been used to characterize the morphological properties of erythrocytes in microfluidic flows. We have obtained the light scattering profiles (LSPs) of individual living cells in microfluidic flows over a wide angular range and matched them with scattering simulations to characterize their morphological properties. The viscoelasticity-induced 3D cell alignment in microfluidic flows has been investigated by bright-field and holographic microscopy tracking, where the latter technique has been used to obtain precise cell alignment profiles in-flow. Such information allows variable cell probability control in microfluidic flows at very low viscoelastic polymer concentrations, obtaining cell measurements that are almost physiological. Our results confirm the possibility of precise, label-free analysis of individual living erythrocytes in microfluidic flows

Effects of a treated sewage effluent on behavioural traits in Diamesa cinerella and Daphnia magna

Recently, the use of Daphnia magna has been proposed in on-line and real-time biomonitoring programmes as an early warning system for evaluating the effluent quality of sewage treatment plants (STPs). These systems are based on recording behavioural changes in the test organism resulting from the stress caused by the effluents. Indeed, altered behavioural signals could be induced at sublethal concentrations that are significantly lower than the corresponding EC50. However, at present, it is unknown whether the sensitivity of D. magna can be representative of that of other aquatic organisms, particularly benthic macroinvertebrates. An experiment was designed to verify whether D. magna can be employed in biomonitoring programmes for STPs located in alpine areas as a surrogate for cold freshwater best-adapted species. The responses of survival and behaviour alteration to exposure to the effluent of the Tonale Pass plant (Trentino, Italian Alps, 46°N, 10°E; 1799 m a.s.l.) were compared in a laboratory population of D. magna and a wild population of the chironomid Diamesa cinerella. These larvae were collected from the Vermigliana stream 50 metres upstream of the effluent input. Both organisms were exposed for 24 and 48 hrs to the effluent as it is and to three dilutions (/10, /100, /1000). The mortality rate and behavioural responses (using video tracking systems) were recorded. No significant mortality or change in behaviour was observed in the two species when exposed to the undiluted effluent. Exposure to serial dilutions of the treated effluent did not affect the survival of either species but notably altered their behaviour at both exposure times (e.g., the time spent in activity in D. magna and the average speed of movement and the cumulative distance travelled in both), especially when exposed to the ten-times-diluted effluent. Overall, the findings of this study emphasize that even though D. magna and D. cinerella use different behavioural strategies to cope with adverse environmental conditions, their overall sensitivity to treated effluents is similar. Accordingly, the use of D. magna in biological early warning systems protocols seems to also be sufficiently protective for local, cold-adapted species of alpine freshwater ecosystems

Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience

: In the present study, we aimed to evaluate the absolute risk of infection in the real-life setting of AML patients treated with CPX-351. The study included all patients with AML from 30 Italian hematology centers of the SEIFEM group who received CPX-351 from July 2018 to June 2021. There were 200 patients included. Overall, 336 CPX-351 courses were counted: all 200 patients received the first induction cycle, 18 patients (5%) received a second CPX-351 induction, while 86 patients (26%) proceeded with the first CPX-351 consolidation cycle, and 32 patients (10%) received a second CPX-351 consolidation. A total of 249 febrile events were recorded: 193 during the first or second induction, and 56 after the first or second consolidation. After the diagnostic work-up, 92 events (37%) were classified as febrile neutropenia of unknown origin (FUO), 118 (47%) were classifiable as microbiologically documented infections, and 39 (17%) were classifiable as clinically documented infections. The overall 30-day mortality rate was 14% (28/200). The attributable mortality-infection rate was 6% (15/249). A lack of response to the CPX-351 treatment was the only factor significantly associated with mortality in the multivariate analysis [p-value: 0.004, OR 0.05, 95% CI 0.01-0.39]. Our study confirms the good safety profile of CPX-351 in a real-life setting, with an incidence of infectious complications comparable to that of the pivotal studies; despite prolonged neutropenia, the incidence of fungal infections was low, as was infection-related mortality

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies:a report from the EPICOVIDEHA registry

Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).</p

Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p&nbsp;=&nbsp;0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir. Funding: EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)

Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Peer reviewe

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.Peer reviewe